期刊
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
卷 38, 期 17, 页码 5126-5135出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/07391102.2019.1696709
关键词
CDK isoforms; pyrrolone-fused benzosuberene (PBS); MM-PBSA; drug discovery; ligand efficiency
资金
- Board of Research in Nuclear Sciences, Department of Atomic Energy, Mumbai, India [37(1)/14/26/2015/BRNS]
- Department of Science and Technology, New Delhi, India [ECR/2016/000031]
- CSIR [MLP0201, HCP0007]
Cyclin-dependent kinases (CDKs) are known for their vital role in regulating cell cycle progression through protein-kinase interactions. CDKs also help in regulating transcription and development of the central nervous system. Inhibition of CDKs is a very fundamental approach for drug discovery in areas of different types of cancers, Alzheimer's, and HIV infections. The present research focuses on finding a novel, potent, and specific natural inhibitors of CDK isoforms (CDK2, CDK5, CDK7, CDK9). Molecular docking, molecular dynamics (MD) simulations, and Molecular Mechanics Poisson-Boltzmann Surface Area (MM-PBSA) were carried out to get an in-depth understanding of protein-ligand interactions. Based on our molecular docking results, Ligands-3, 5, 14, and 16 were screened among 17 different Pyrrolone-fused benzosuberene compounds as potent and specific inhibitors without any cross-reactivity against different CDK isoforms. Analysis of MD simulations and MM-PBSA studies, revealed the binding energy profiles of all the selected complexes. Our selected ligands performed better than the standard inhibitor (Roscovitine). Ligands-3 and 14 show specificity for CDK7 and Ligands-5 and 16 were specific against CDK9. These ligands are expected to possess lower risk of side effects due to their natural origin. Moreover, the backbone structure of these ligands could also be exploited to develop specific inhibitors against other CDK isoforms. Communicated by Ramaswamy H. Sarma
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据